The BEACON Study (Breast Cancer Outcomes With NKTR-102)

Completed · Phase 3

Conditions studied: Locally Recurrent Breast Cancer, Metastatic Breast Cancer

In brief

The study is designed as an open-label, randomized, parallel, two arm, multicenter, international Phase 3 study in patients with recurrent or metastatic breast cancer previously treated with cytotoxic chemotherapy regimens. The primary study objective is to compare overall survival of patients who receive NKTR-102 given once every 21 days to patients who receive treatment of Physician's Choice selected from a list of seven single-agent intravenous therapies.

Key facts

Study ID
NCT01492101
Run by
Nektar Therapeutics
People needed
852
Starts
2011-12-01
Expected to finish
2016-06-01
Last updated by the study team
2021-06-01

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.